Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 09, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 3,875,000 Ordinary shares of 25 pence each.
- Repurchase Price: 1,297.86 pence per share.
- Treasury Shares Held: 350,949,158 shares (representing 6.19% of total voting rights).
- Shares in Issue: 5,671,049,875 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the open market purchase of 3,875,000 shares on August 09, 2007. Consequently, the total number of shares held in Treasury increased to 350,949,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the share repurchase by multiplying the 3,875,000 shares by the 1,297.86 pence price.
- Confirm the updated total voting rights denominator (5,671,049,875 shares) for compliance with disclosure thresholds.
- Review the company's broader capital allocation strategy to understand the context of this specific buyback within the fiscal year.